Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG NASDAQ:EWTX NASDAQ:GPCR NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$88.18+2.3%$80.49$23.17▼$123.75$858.00M-5.35172,433 shs36,882 shsEWTXEdgewise Therapeutics$37.08-2.5%$31.28$12.15▼$39.96$3.99B0.251.01 million shs775,241 shsGPCRStructure Therapeutics$41.15+0.1%$52.99$15.80▼$94.90$2.92B-1.311.02 million shs224,531 shsNAMSNewAmsterdam Pharma$30.46+2.0%$31.90$16.78▼$42.00$3.50B0.02824,761 shs231,583 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences-0.85%-3.11%+20.65%+13.45%+176.26%EWTXEdgewise Therapeutics+24.18%+22.65%+14.04%+33.51%+129.81%GPCRStructure Therapeutics-2.63%-5.65%-23.15%-49.42%+49.18%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$88.18+2.3%$80.49$23.17▼$123.75$858.00M-5.35172,433 shs36,882 shsEWTXEdgewise Therapeutics$37.08-2.5%$31.28$12.15▼$39.96$3.99B0.251.01 million shs775,241 shsGPCRStructure Therapeutics$41.15+0.1%$52.99$15.80▼$94.90$2.92B-1.311.02 million shs224,531 shsNAMSNewAmsterdam Pharma$30.46+2.0%$31.90$16.78▼$42.00$3.50B0.02824,761 shs231,583 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences-0.85%-3.11%+20.65%+13.45%+176.26%EWTXEdgewise Therapeutics+24.18%+22.65%+14.04%+33.51%+129.81%GPCRStructure Therapeutics-2.63%-5.65%-23.15%-49.42%+49.18%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 2.86Moderate Buy$128.6045.84% UpsideEWTXEdgewise Therapeutics 2.89Moderate Buy$38.132.83% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$109.25165.49% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0057.61% UpsideCurrent Analyst Ratings BreakdownLatest DRUG, NAMS, EWTX, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026EWTXEdgewise Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$101.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$101.004/21/2026GPCRStructure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026DRUGBright Minds Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.003/30/2026DRUGBright Minds Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$147.003/26/2026GPCRStructure Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/18/2026NAMSNewAmsterdam Pharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$57.003/17/2026GPCRStructure Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$145.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/ANAMSNewAmsterdam Pharma$22.50M155.62N/AN/A$5.97 per share5.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$8.74M-$1.93N/AN/AN/AN/A-28.62%-28.08%5/15/2026 (Estimated)EWTXEdgewise Therapeutics-$167.79M-$1.63N/AN/AN/AN/A-31.97%-30.46%5/7/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.79N/AN/AN/AN/A-25.90%-24.54%5/7/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.73N/AN/AN/A-906.22%-26.67%-24.82%5/7/2026 (Estimated)Latest DRUG, NAMS, EWTX, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026DRUGBright Minds Biosciences-$0.8686N/AN/AN/AN/AN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50N/AN/AN/AN/AN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39N/AN/AN/A$10.00 millionN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46N/AN/AN/A$1.09 millionN/A2/26/2026Q4 2025EWTXEdgewise Therapeutics-$0.43-$0.47-$0.04-$0.47N/AN/A2/26/2026Q4 2025GPCRStructure Therapeutics-$0.35-$0.49-$0.14$999.00$7.14 millionN/A2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 million2/12/2026Q1 2026DRUGBright Minds Biosciences-$0.98-$0.70+$0.28-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A57.3857.38EWTXEdgewise TherapeuticsN/A19.8519.85GPCRStructure TherapeuticsN/A24.8124.81NAMSNewAmsterdam PharmaN/A7.887.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%EWTXEdgewise TherapeuticsN/AGPCRStructure Therapeutics91.78%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%EWTXEdgewise Therapeutics23.20%GPCRStructure Therapeutics5.60%NAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableEWTXEdgewise Therapeutics60107.48 million82.55 millionOptionableGPCRStructure Therapeutics13670.84 million66.88 millionOptionableNAMSNewAmsterdam Pharma4114.97 million91.01 millionOptionableDRUG, NAMS, EWTX, and GPCR HeadlinesRecent News About These CompaniesNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comPictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMSMay 1, 2026 | marketbeat.comJennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMSApril 30, 2026 | marketbeat.comNewAmsterdam Pharma (NAMS) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.com143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLCApril 29, 2026 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - What's Next?April 28, 2026 | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 15, 2026 | marketbeat.comA Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C ResultsApril 10, 2026 | finance.yahoo.comNewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells FargoApril 8, 2026 | theglobeandmail.comNewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan DruckenmillerApril 8, 2026 | msn.comNewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comBillionaire Stan Druckenmiller’s 5 Small and Mid-Cap Stock Picks with Huge Upside PotentialApril 7, 2026 | insidermonkey.comAberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSApril 6, 2026 | marketbeat.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comHere’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4April 2, 2026 | finance.yahoo.comUpcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)March 29, 2026 | finance.yahoo.comNewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionMarch 23, 2026 | globenewswire.comNewAmsterdam Pharma shows market leadership with jump to 84 RS ratingMarch 18, 2026 | msn.comTracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q4 2025 UpdateMarch 11, 2026 | seekingalpha.comNewAmsterdam Pharma Co. N.V.March 10, 2026 | barrons.comJohannes Jacob Piete Kastelein Sells 94,124 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockMarch 10, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Simply Good Foods Stock Just Had Its Worst Day in YearsBy Chris Markoch | April 10, 20263 Ways to Invest in the Growing GLP-1 Weight Loss MarketBy Nathan Reiff | April 17, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentBy Nathan Reiff | May 1, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026DRUG, NAMS, EWTX, and GPCR Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$88.18 +1.96 (+2.27%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Edgewise Therapeutics NASDAQ:EWTX$37.08 -0.93 (-2.46%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$41.15 +0.05 (+0.12%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.NewAmsterdam Pharma NASDAQ:NAMS$30.46 +0.61 (+2.03%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
